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Over the past few decades, there has been growingevidence for an association between regular cannabis
use and psychotic symptoms and disorders, both in the general
population (1,2) and among incident cases of schizophrenia
and other psychoses (3–5). This association prompts the ques-
tion, Is cannabis use a contributory cause of psychosis?
It is useful to distinguish 2 ways in which cannabis use could
cause psychosis (6). The strongest hypothesis is that heavy
cannabis use causes a psychosis that would not have occurred
in the absence of cannabis. A second, weaker hypothesis is
that cannabis use is a contributory cause in the sense that it
may precipitate schizophrenia in individuals vulnerable to the
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Objective: To assess whether cannabis use in adolescence and young adulthood is a
contributory cause of schizophreniform psychosis in that it may precipitate psychosis in
vulnerable individuals.
Method: We reviewed longitudinal studies of adolescents and young adults that examined
the relations between self-reported cannabis use and the risk of diagnosis with a psychosis
or of reporting psychotic symptoms. We also reviewed studies that controlled for potential
confounders, such as other forms of drug use and personal characteristics that predict an
increased risk of psychosis. We assessed evidence for the biological plausibility of a
contributory causal relation.
Results: Evidence from 6 longitudinal studies in 5 countries shows that regular cannabis
use predicts an increased risk of a schizophrenia diagnosis or of reporting symptoms of
psychosis. These relations persisted after controlling for confounding variables, such as
personal characteristics and other drug use. The relation did not seem to be a result of
cannabis use to self-medicate symptoms of psychosis. A contributory causal relation is
biologically plausible because psychotic disorders involve disturbances in the dopamine
neurotransmitter systems with which the cannabinoid system interacts, as demonstrated by
animal studies and one human provocation study.
Conclusion: It is most plausible that cannabis use precipitates schizophrenia in individuals
who are vulnerable because of a personal or family history of schizophrenia.
(Can J Psychiatry 2006;51:556–565)
Information on funding and support and author affiliations appears at the end of the article.
Highlights
 This review summarizes recent key prospective studies that provide consistent evidence that
cannabis use may be a contributory cause of psychosis.
 It also synthesizes these studies in light of other evidence on the biological plausibility of the
association.
 The clinical, regulatory, and policy implications of the evidence are discussed in the
companion paper to this review (Hall and Degenhardt, Can J Psychiatry 2006;51:566–74).
illness. The second hypothesis assumes that cannabis use is
one factor among many others (including genetic predisposi-
tion and other unknown causes) that act together to cause
schizophrenia.
These are not the only possible explanations of the associa-
tion (6–15). It is possible that cannabis use and psychosis are
caused by common factors that increase the risk of both, or
that individuals with schizophrenia use cannabis to self-
medicate the symptoms of their disorder.
To infer that cannabis use causes psychosis in any of these
ways, we need evidence of several things: an association
between cannabis use and psychosis, that this association is
greater than expected by chance, that cannabis use precedes
psychosis, and that we can exclude plausible alternative
explanations of this association (16). Evidence of the associa-
tion between cannabis use and psychosis, as well as evidence
that chance is an unlikely factor in this association, is readily
available. Several prospective studies also show that cannabis
use precedes psychosis. The difficulty lies in excluding the
hypothesis that the relation between cannabis use and psycho-
sis is due to other factors (for example, other drug use or a
genetic predisposition to develop schizophrenia and
subsequently use cannabis to self-medicate).
Cannabis as a Cause of Psychosis
A Specific Cannabis Psychosis
There are case reports of cannabis psychoses (17–21) describ-
ing individuals who develop psychotic disorders after using
cannabis (22). These disorders have been attributed to canna-
bis use for combinations of the following reasons: the onset of
the disorders followed the use of large quantities of cannabis;
the affected individuals were confused, disorientated, and
amnesic; some individuals had no personal or family history
of psychosis; some individuals’ symptoms remitted within
days to weeks of enforced abstinence from cannabis; some
individuals recovered completely and had no residual psy-
chotic symptoms like those consistent with schizophrenia;
and if the disorder recurred, it was only after the individual
resumed cannabis use (6). Some commentators have criti-
cized these case reports because they provide poor informa-
tion on cannabis use and its relation to the onset of psychosis,
the individual’s premorbid adjustment, and the family history
of psychosis (11,12). A recent retrospective study of Danish
clinical registers found that most individuals with clinician-
diagnosed, cannabis-induced psychotic disorders were
subsequently diagnosed with schizophrenia or another
psychotic disorder (21).
Psychotic Symptoms and Cannabis Use
It is possible that cannabis use might trigger symptoms of psy-
chosis among some users. This is distinct from a specific psy-
chotic disorder attributable to cannabis use. Other drugs, such
as amphetamines, also have the potential to trigger psychotic
symptoms among some users (23). This possibility is also bio-
logically plausible given the increasing evidence about the
nature of the effects of cannabis on the brain (see discussion
below). One study used an experimental design (as was used
in the 1960s with amphetamines; 23) to show that intrave-
nously administering THC to healthy volunteers without psy-
chosis increased positive and negative psychotic symptoms in
a dose-dependent way (24). It is important to note that effects
on symptoms are clinically (and importantly) distinct from a
psychotic disorder such as schizophrenia.
Several studies examined the relation between cannabis use
and psychotic symptoms in the general population. Tien and
Anthony used data from the ECA to examine correlates of
reporting one or more psychotic experiences (that is, 4 types
of hallucinations and 7 types of delusional beliefs), using a
case–control design (2). They compared 477 individuals who
reported one or more of these symptoms in a 1-year follow-up
with 1818 control subjects who did not. Participants were
matched for age and social and demographic characteristics.
They found that daily cannabis use doubled the risk of
reported psychotic symptoms (after statistical adjustment for
alcohol use and psychiatric diagnoses at baseline).
Thomas reported the prevalence of psychotic symptoms
among cannabis users in a random sample of individuals
drawn from the electoral roll of a large city in the North Island
of New Zealand (25). After using cannabis, 1 in 7 (14%) indi-
viduals reported strange, unpleasant experiences, such as
hearing voices, having fears of persecution, or worrying that
someone was attempting to harm them (25).
Stefanis and others reported cross-sectional relations between
self-reported cannabis use and positive and negative symp-
toms of psychosis at age 18 years in a cohort of 3500 Greek
adolescents (26). The rate of cannabis use was low, with only
6% reporting lifetime use and 0.9% reporting daily or near
daily use. Nonetheless, they found positive associations
between frequency of cannabis use (never, once, 2 to 4 times,
5 times or more, and daily or near daily) and 4 dimensions of
psychotic experiences (paranoid, first rank, hallucinations,
and grandiose experiences). These relations were not affected
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Abbreviations used in this article
COMT catechol-O-methyltransferase
ECA Epidemiologic Catchment Area studyI
NSMHWB National Survey of Mental Health and Well-Being
RR relative risk
SCL-90 Symptom Checklist, 90-item
THC delta-9-tetrahydrocannabinol
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Table 1 Summary of recent longitudinal studies examining the relation between cannabis and psychosis
Study Participants Drug measures Psychosis measures Main findings
Christchurch (54) Study of young adults
aged 18 to 21 years in
Christchurch
Cannabis dependence
according to DSM-IV
criteria
Assessed with 10 items
from the SCL-90
Dependence at age 18
years predicted increased
risk of psychotic
symptoms at age 21
years, after controlling for
other factors such as
other drug use and other
psychiatric disorders
Dunedin (53) Analysis of data from a
birth cohort in New
Zealand (n = 759)
Self-reported cannabis
use
Assessed according to
DSM-IV criteria;
symptoms assessed at
age 11 years; also looked
at functional
polymorphism of COMT
gene that codes for
dopamine and risk of
psychosis
25% who were
homozygous for a
polymorphism and used
cannabis were much
more likely to develop
schizophreniform
disorders than those with
a polymorphism who did
not use cannabis; in the
absence of a
polymorphism, those who
used cannabis were not
at increased risk of
psychosis
Stefanis (26) 3500 Greek adolescents
aged 18 years
Self-reported cannabis
use and frequency of
cannabis use: never,
once, 2 to 4 times, > 5
times, daily or near daily
use
Paranoia, first rank,
hallucinations, grandiose
experiences
Positive association
found between frequency
of cannabis use and
psychotic measures, after
controlling for other drug
use and depressive
symptoms; association
stronger for those
reporting initiation of
cannabis use before age
15 years
van Os (50) Study over 3 years of
4848 people drawn from
a community in The
Netherlands
Self-reported cannabis
and other drug use at
baseline and follow-up,
as well as frequency of
use
Assessed by
computerized diagnostic
interview at baseline and
follow-up
Cannabis use at baseline
predicted increased risk
of psychotic symptoms at
follow-up; the greater the
frequency of use at
baseline, the greater the
risk of psychotic
symptoms at follow-up;
relation remained when
other drug use was
controlled for; relation
stronger for those with
more severe psychotic
symptoms
Henquet (51) Study over 4 years of
2437 adolescents and
young adults in Munich
Self-reported cannabis
use at baseline and
follow-up, as well as
frequency of cannabis
use
Assessed in early
adulthood with the
Computerized Composite
International Diagnostic
Interview at baseline and
follow-up
Dose–response relation
found between cannabis
use at baseline and
likelihood of reporting
psychotic symptoms;
those with psychotic
symptoms at baseline
were more likely to report
symptoms at follow-up if
they used cannabis than
were those who did not
use cannabis
by controlling for other drug use or symptoms of depression.
They were also stronger in individuals who reported initiation
of cannabis use prior to age 15 years.
Community surveys of psychiatric disorders, such as the
ECA, have reported higher rates of substance use disorders
among individuals with schizophrenia (27). Nearly one-half
of the patients identified in the ECA as having schizophrenia
were also diagnosed with substance abuse or dependence
(34% for an alcohol disorder and 28% for another drug disor-
der) (28). These rates were higher than those among the gen-
eral population, which were 14% for alcohol disorders (29)
and 6% for drug abuse (27). The most common patterns of
substance use among the 231 individuals with schizophrenia
in the ECA were alcohol (37%) and cannabis (23%), stimu-
lants and hallucinogens (13%), and narcotics (10%) and
sedatives (8%) (30).
The NSMHWB, conducted in Australia in 1997, included a
screening questionnaire for psychotic symptoms (31). Among
those under age 50 years who screened positive for a psy-
chotic disorder, 7.8% (n = 27) met ICD-10 criteria for canna-
bis dependence in the past 12 months. This was 17.2% of all
individuals diagnosed with cannabis dependence. A diagnosis
of cannabis dependence made the chances of reporting psy-
chotic symptoms 1.71 times more likely, after adjusting for
age, affective and anxiety disorders, smoking status, and alco-
hol dependence (1). In the NSMHWB, 11.5% of individuals
who reported being diagnosed with schizophrenia met
ICD-10 criteria for a cannabis use disorder in the prior 12
months, and 21.2% met criteria for an alcohol use disorder.
After adjusting for confounding variables, those who met cri-
teria for cannabis dependence were 2.9 times more likely to
report that they had been diagnosed with schizophrenia than
those who did not.
Cannabis Use and Schizophrenia
Clinical Studies
In case–control studies, patients with schizophrenia are more
likely to use cannabis than other psychiatric patients or control
subjects without schizophrenia (32–34). The prevalence of
cannabis use in patients with schizophrenia varies among
studies, but it is generally higher than the rates in the general
population (34,35). These variations are probably owing to
differences in the sampling of patients, with younger individ-
uals reporting higher rates of cannabis use than older individ-
uals with chronic disorders. After alcohol and tobacco,
cannabis is the most commonly used drug, and it is often used
with alcohol (36,37).
Apart from finding that young men are overrepresented
among cannabis users (6), as they are in the general commu-
nity (38), the controlled clinical studies provide conflicting
evidence on the correlates of substance abuse in schizophre-
nia. In some studies, cannabis users had an earlier onset of
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Table 1 continued
Study Participants Drug measures Psychosis measures Main findings
Ferdinand (61) Study over 14 years of
1580 adolescents and
young adults in
The Netherlands
Self-reported cannabis
use
Assessed using the
Computerized Composite
International Diagnostic
Interview
Findings indicate
bidirectional relation
between cannabis use
and psychosis; early
cannabis use predicted
psychotic symptoms after
adjusting for preexisting
psychopathology;
psychotic symptoms in
those who had not used
cannabis before the onset
of psychotic symptoms
predicted future cannabis
use
Zammit (49) Study over 27 years of
individuals aged 18 to 20
years
Self-reported cannabis
use and frequency of use
Schizophrenia assessed
according to DSM-IV
criteria
Cannabis use at baseline
predicted increased risk
of schizophrenia at follow-
up, after controlling for
other drug use and
potential confounders; the
more frequent the
cannabis use at baseline,
the greater the risk of
schizophrenia at follow-up
psychotic symptoms, a better premorbid adjustment, more
episodes of illness, and more hallucinations (36,39–42).
Other controlled studies failed to replicate some of these
findings (30,43–46).
A recent clinical study adopted a novel approach to studying
the relation between cannabis use and psychosis (47). In this
study, 100 young individuals (49% male with an average age
of 19.3 years) were identified as being at ultra high risk of psy-
chosis on the basis of one or more criteria: schizophrenia in a
first-degree relative, the presence of attenuated psychotic
symptoms, or a brief, limited psychosis. Cannabis was the
most commonly used drug in the 12 months preceding the
assessment (35%), with 18% of participants meeting criteria
for cannabis dependence in the previous year. Cannabis use,
however, did not predict an increased risk of developing an
acute psychosis during the follow-up period, regardless of
whether cannabis use in the past year was defined as any use,
frequent use, or dependent use.
Prospective Studies of Cannabis and Psychosis
The first convincing evidence that cannabis use may precipi-
tate schizophrenia came from a 15-year prospective study of
cannabis use and schizophrenia in 50 465 Swedish individu-
als (48). This study investigated the relation between
self-reported cannabis use at age 18 years and the risk of being
diagnosed with schizophrenia, as documented in the Swedish
psychiatric case register, during the subsequent 15 years.
Andreasson and others found that those who tried cannabis by
age 18 years were 2.4 times more likely to receive a schizo-
phrenia diagnosis than those who had not. The risk of a
schizophrenia diagnosis was related in a dose–response way
to the number of times cannabis had been used by age 18
years. Compared with those who had not used cannabis, the
risk of developing schizophrenia was 1.3 times higher for
individuals who had used cannabis 1 to 10 times. It was 3
times higher for individuals who had used cannabis between 1
and 50 times. For individuals who had used cannabis more
than 50 times, the risk of developing schizophrenia was 6
times higher, compared with those who had not used
cannabis.
These risks were substantially reduced after statistical adjust-
ment for variables related to the risk of developing schizo-
phrenia. These included having a psychiatric diagnosis at age
18 years and having divorced parents (as an indicator of
parental psychiatric disorder). Nevertheless, these relations
remained statistically significant after the adjustment. Com-
pared with individuals who never used cannabis, those who
used cannabis 1 to 10 times were 1.5 times more likely to
receive a schizophrenia diagnosis. Those who used cannabis
10 times or more were 2.3 times more likely to receive a
schizophrenia diagnosis. Andreasson and others argued that
this means that cannabis use precipitates schizophrenia in
vulnerable individuals (48).
Several longitudinal studies have since supported the findings
of Andreasen and others’ study (Table 1). As a follow-up to
the Swedish cohort study, Zammit and others reported risk
over 27 years, which covers most of the risk period for the
onset of psychotic disorders in a cohort that was first studied at
age 18 to 20 years (49). This study improved on the earlier
study in several ways: the psychiatric register provided more
complete coverage of all individuals diagnosed with schizo-
phrenia; statistical control was improved and included a larger
number of potential confounding variables, such as other drug
use, IQ, known risk factors for schizophrenia, and social inte-
gration; to examine the possible role of a prodrome, the study
distinguished between cases that occurred in the first 5 years
of the study period and those that occurred more than 5 years
afterwards; and the study undertook separate analyses of indi-
viduals who only reported using cannabis at the initial
assessment.
Zammit and others, as did Andreasen and others, found that
cannabis use at baseline predicted an increased risk of schizo-
phrenia during the follow-up period. They also found a
dose–response relation between frequency of cannabis use at
baseline and risk of schizophrenia during the follow up. They
demonstrated that the relation between cannabis use and
schizophrenia persisted when they statistically controlled for
the effects of other drug use and other potential confounding
factors, including a history of psychiatric symptoms at base-
line. They estimated that 13% of schizophrenia cases could be
averted if all cannabis use was prevented (that is, there was an
attributable risk of 13% owing to cannabis use). The relation
between cannabis use and schizophrenia was the same for the
subset of the sample of individuals who only reported canna-
bis use at baseline, for individuals diagnosed during the first 5
years after assessment, and for individuals diagnosed during
the subsequent 22 years. The relation was slightly stronger in
cases observed during the first 5 years, which probably
reflects the decline in cannabis use that occurs with age.
Zammit and others’ findings were consistent with those of a
study conducted by van Os and colleagues (50). This was a
3-year longitudinal study of the relation between self-reported
cannabis use and psychosis in a community sample of 4848
individuals in The Netherlands. At baseline, subjects were
assessed on cannabis and other drug use. Psychotic symptoms
were assessed with a computerized diagnostic interview. Psy-
chosis diagnoses were validated by diagnostic telephone
interview with a psychiatrist or a psychologist. A consensus
clinical judgment as to whether individuals had a psychotic
disorder for which they needed psychiatric care was made on
the basis of the interview material.
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van Os and others substantially replicated the findings of the
Swedish cohort and extended them in several important ways:
cannabis use at baseline predicted an increased risk of psy-
chotic symptoms during the follow-up period in individuals
who did not report psychiatric symptoms at baseline; there
was a dose–response relation between frequency of cannabis
use at baseline and risk of psychotic symptoms during the
follow-up period; those who reported any psychotic symp-
toms at baseline were more likely to develop schizophrenia if
they used cannabis than were less vulnerable individuals ; the
relation between cannabis use and psychotic symptoms per-
sisted when van Os and others statistically controlled for the
effects of other drug use; and the relation between cannabis
use and psychotic symptoms was stronger for individuals with
more severe psychotic symptoms who were judged to need
psychiatric care. van Os and others estimated that, for individ-
uals suffering from psychosis who were judged to need psy-
chiatric treatment, cannabis is responsible for 13% of the risk
of psychotic symptoms. They also estimated that cannabis is
responsible for 50% of this risk for individuals with psychotic
disorders who were judged to need psychiatric treatment.
A study by Henquet and others also replicated the Swedish
and Dutch studies in a 4-year follow-up of a cohort of 2437
adolescents and young adults between 1995 and 1999 in
Munich (51). At baseline, subjects were assessed by a ques-
tionnaire on cannabis use and psychotic symptoms. Psychotic
symptoms were assessed, in early adulthood with the Com-
puterized Composite International Diagnostic Interview.
They found a dose–response relation between self-reported
cannabis use at baseline and the likelihood of reporting psy-
chotic symptoms. As in the Dutch cohort, young individuals
who reported psychotic symptoms at baseline were much
more likely to experience psychotic symptoms at follow-up if
they used cannabis than were their peers who did not have
such a history.
Arsenault and others reported a prospective study of the rela-
tion between adolescent cannabis use and psychosis in young
adults in a New Zealand birth cohort (n = 759) whose mem-
bers were assessed intensively from birth on risk factors for
psychotic symptoms and disorders (52). Psychotic disorders
were conservatively assessed according to DSM-IV diagnos-
tic criteria, with corroborative reports on social adjustment
from family members or friends. The researchers assessed
psychotic symptoms at age 11 years, before the onset of can-
nabis use, and distinguished between early- and late-onset
cannabis use. They also examined the specificity of the asso-
ciation between cannabis use and psychosis by analyzing the
effects of other drug use on psychotic symptoms and disorders
and of cannabis use on depressive disorders.
Arsenault and others found a relation between cannabis use by
age 15 years and an increased risk of psychotic symptoms by
age 26 years. Controlling for other drug use did not affect the
relation. After adjusting for psychotic symptoms reported at
age 11 years, the relation was no longer statistically signifi-
cant, which probably reflected the small number of psychotic
disorders observed in the sample. The small number of partic-
ipants also limited the study’s ability to examine predictors of
psychotic disorders at age 26 years. The measurement of can-
nabis and other drug use was crude (that is, none, 1 to 2 times,
and 3 or more times); however, this was more likely to work
against finding relations. The specificity of the effects of can-
nabis on psychotic symptoms was interesting: there was no
relation between other drug use and psychotic disorders, and
there was no relation between cannabis use and depression.
There was also an interaction between psychosis risk and age
of onset of cannabis use; earlier onset was more strongly
related to psychosis. Arsenault and others also suggested an
interaction between cannabis use and vulnerability, with a
higher risk of psychosis among cannabis users who reported
psychotic symptoms at age 11 years.
Caspi and colleagues subsequently analyzed data from this
cohort and reported an interaction between the risk of psycho-
sis, cannabis use, and a functional polymorphism of the
COMT gene that codes for dopamine (53). They found that
the individuals in the 25% of the cohort that was homozygous
for a polymorphism and used cannabis were 10.9 times more
likely to develop a schizophreniform disorder than their peers
with the same polymorphism who did not use cannabis. In the
absence of this polymorphism, young adults who used canna-
bis were not at any increased risk of psychosis.
Fergusson, Horwood, and Swain-Campbell conducted a lon-
gitudinal study of the relation between cannabis dependence
at age 18 years and the number of psychotic symptoms
reported at age 21 years in the Christchurch birth cohort in
New Zealand (54). They assessed cannabis dependence
according to DSM-IV criteria and psychotic symptoms
according to 10 items from the SCL-90. Because this birth
cohort was assessed throughout childhood and adolescence,
Fergusson and colleagues were able to adjust for a large num-
ber of potential confounding variables, including self-
reported psychotic symptoms at the previous assessment,
other drug use, and other psychiatric disorders. They found
that cannabis dependence at age 18 years predicted an
increased risk of psychotic symptoms at age 21 years (RR
2.3). This association was smaller but still significant after
adjustment for potential confounders (RR 1.8). More
recently, Fergusson and colleagues used a more sophisticated
structural equations modelling design that accounted for both
observed and nonobserved confounding factors to examine
the association between cannabis use and psychotic
symptoms until the individuals in this cohort were aged 25
years (55). Consistent with their earlier study, they concluded
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that the association between cannabis and psychosis did not
appear to be a result of confounding factors and that the asso-
ciation appeared to move from cannabis use to symptoms of
psychosis, rather than vice versa.
The longitudinal studies find consistent associations between
cannabis use in adolescence and the occurrence of psychotic
symptoms in early adulthood, but all share a weakness: the
temporal relation between cannabis use and the onset of psy-
chotic symptoms is uncertain. Subjects in these studies are
usually assessed once each year or less often and asked to
report retrospectively on their cannabis use during the preced-
ing number of years (often as crudely as the number of times
cannabis was used or the number of times it was used weekly
or monthly).
According to an experience sampling method, a French study
by Verdoux and others provides greater detail on the temporal
relation between cannabis use and psychotic symptoms (56).
These investigators asked 79 college students to report their
drug use and experience of psychotic symptoms at randomly
selected time points, several times daily for 7 consecutive
days. The students carried portable electronic devices through
which ratings were prompted by randomly programed sig-
nals. The students comprised a stratified sample from a larger
group; thus, high cannabis users (n = 41) and students identi-
fied as vulnerable to psychosis (n = 16) were overrepresented
in the sample. Vulnerability to psychosis was determined dur-
ing a personal interview and indicated by reporting one or
more psychotic symptoms in the month prior to the study.
Verdoux and others found a positive association between
self-reported cannabis use and unusual perceptions; they
found a negative association between cannabis use and hostil-
ity. That is, during periods of cannabis use, users reported
more unusual perceptions and less hostility. These relations
depended on vulnerability to psychosis: in vulnerable individ-
uals cannabis use was more strongly associated with strange
impressions and unusual perceptions, and its use did not
decrease feelings of hostility as it did in individuals who
lacked this vulnerability.
Self-Medication
The self-medication hypothesis is superficially plausible, but
the evidence in its favour is not very compelling (8). The rea-
sons that most individuals with schizophrenia use alcohol,
cannabis, and other illicit drugs are similar to those of individ-
uals who do not have schizophrenia: to relieve boredom, to
provide stimulation, to feel good, and to socialize with
peers (37,57,58). The drugs that are most often used by
patients with schizophrenia are also those that are used by
their peers: tobacco, alcohol, and cannabis.
In favour of the self-medication hypothesis is the evidence
that some patients with schizophrenia report using cannabis
because its euphoric effects relieve negative symptoms and
depression (32,42,57,59). Dixon and others, for example, sur-
veyed 83 patients with schizophrenia who reported that can-
nabis reduced anxiety and depression and that it increased a
sense of calm, but at the cost of increased suspiciousness (42).
Similar results were found in a recent Australian study (57).
The self-medication hypothesis has not typically been sup-
ported (51,55). Several prospective epidemiologic studies
found that there was no relation between early psychotic
symptoms and an increased risk of later cannabis use, which
the self-medication hypothesis requires. The relation flowed
from early cannabis use to psychosis rather than vice versa.
Such negative results are supported by a study by Verdoux
and others that used an experience sampling method to exam-
ine the temporal relation between cannabis use and psychotic
symptoms (60). They found that there was no temporal rela-
tion between reporting unusual experiences and using canna-
bis, as would occur if self-medication were involved. One
study of adolescents (younger than the above studies) was an
exception. Ferdinand and others found an association (unad-
justed for confounding variables) between early-onset psy-
chotic symptoms and later cannabis use among this younger
group (61). However, the authors did not discuss the possibil-
ity that there was an interaction between genetic vulnerabili-
ties to psychosis and cannabis use as well as correlations
between genetic vulnerabilities and cannabis use, which were
purported by some commentators as possible factors to con-
sider in the findings of the Ferdinand study (62). It is also pos-
sible that the unique changes of adolescence affected the
nature of the relation between emerging psychotic symptoms
and cannabis use (63). A later analysis of data from this cohort
found more support for a causal role of cannabis use. Early
cannabis use predicted psychotic symptoms after adjusting
for preexisting psychopathology assessed by the Child
Behavior Checklist (64).
Intervention Studies
If we could reduce cannabis use among patients with schizo-
phrenia we could discover whether their disorders improved
and whether their risk of relapse diminished. The major diffi-
culty with this strategy is that it presupposes that we can suc-
cessfully treat substance use disorders in individuals with
schizophrenia. There are very few controlled outcome studies
of substance abuse treatment in schizophrenia (65). Too few
of these have produced large enough benefits of treatment or
treated a large enough number of patients to provide an ade-
quate chance of detecting any positive effects of abstinence on
the course of disorders. Those that have been large enough
have not reported results separately by diagnosis (66).
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Biological Plausibility
THC, which acts on a specific cannabinoid receptor (CB1)
in the brain, is the principal psychoactive ingredient of canna-
bis (67). While historically the brain’s dopaminergic system
was thought to play an important role in psychotic disor-
ders (68), there is increasing evidence that the cannabinoid
system may be involved in schizophrenia and related psy-
chotic disorders (69–72). CB1 receptor knockout mice, for
example, show behaviours consistent with some schizophre-
nia symptoms, such as reduced goal-directed activity and
memory for temporal representations (70). Elevated levels of
anandamide, an endogenous cannabinoid agonist, have also
been found in the cerebrospinal fluid of individuals with
schizophrenia (73). A recent case–control study found that
individuals with schizophrenia had a greater density of CB1
receptors in the prefrontal cortex, compared with control
subjects (74).
A double-blind provocation study by D’Souza and colleagues
showed that intravenous THC provokes positive and negative
psychotic symptoms in a dose-dependent way in healthy vol-
unteers (75). Caspi and others found a strong interaction
between cannabis use and a common polymorphism in the
COMT gene that suggests a biological basis for the relation
that, if replicated, would explain why the risk of developing a
psychosis after using cannabis is modest in the population as a
whole (53).
The Role of Cannabis Potency
It is sometimes claimed that current cannabis is a different
drug from that used in the 1970s and early 1980s (76). The
United States is the only country that has analyzed the THC
content of cannabis products over the past 3 decades. These
data show an increase in THC content from 1.5% in the early
1970s, to 3.3% in the mid 1980s, and to 4.4% in 1998 (77).
More recent European studies indicate that cultivars of canna-
bis with much higher THC are now being produced in The
Netherlands (78,79), the use and effects of which will need to
be investigated.
The increase in average THC content has overshadowed
another important determinant of exposure to THC: a sharp
decline in the age of initiation of cannabis use between 1970
and 2000 and a consequent increase in rates of regular canna-
bis use (80). These changes in patterns of use have increased
both the amount of THC consumed and the duration of such
consumption among adolescent cannabis users (76), thereby
increasing their risk of dependence, poor educational perfor-
mance, and psychotic symptoms.
Summary
There is currently good epidemiologic evidence from longitu-
dinal studies in several different countries that regular
cannabis use predicts an increased risk of schizophrenia and
that this relation persists after controlling for confounding
variables. There is very weak evidence that this relation is
owing to self-medication. A contributory causal relation is
also biologically plausible. Psychotic disorders involve dis-
turbances in the dopamine neurotransmitter systems and
cannabinoids, such as THC, increase dopamine release in the
nucleus accumbens (81).
The evidence from prospective epidemiologic studies sug-
gests that it is most likely that cannabis use precipitates
schizophrenia in individuals who are vulnerable because of a
personal or family history of schizophrenia. This hypothesis is
consistent with the stress–diathesis model of schizo-
phrenia (82,83) and evidence that a genetic vulnerability to
psychosis increases the risk that cannabis users will develop
psychosis (52,53,56,84). A vulnerability hypothesis is also
consistent with the fact that the treated incidence of schizo-
phrenia did not obviously increase during the 1970s and
1980s (85,86) when there were substantial increases in
cannabis use among young adults in Australia and North
America (38).
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Résumé : L’usage du cannabis est-il une cause concourante de la psychose?
Objectif : Évaluer si l’usage du cannabis à l’adolescence et au jeune âge adulte est une cause
concourante de la psychose schizophréniforme, en ce qu’il peut précipiter la psychose chez les
personnes vulnérables.
Méthode : Nous avons examiné les études longitudinales d’adolescents et de jeunes adultes qui
portaient sur les relations entre l’usage autodéclaré du cannabis et le risque de recevoir un
diagnostic de psychose ou de déclarer des symptômes psychotiques. Nous avons aussi examiné les
études qui contrôlaient d’éventuelles variables confusionnelles, comme l’usage d’autres formes de
drogue et des caractéristiques personnelles qui prédisent un risque accru de psychose. Nous avons
évalué les données probantes de la plausibilité biologique d’une relation causale concourante.
Résultats : Les données probantes de 6 études longitudinales menées dans 5 pays indiquent que
l’usage régulier du cannabis prédit un risque accru d’un diagnostic de schizophrénie ou de déclarer
des symptômes de psychose. Ces relations persistaient après le contrôle des variables
confusionnelles comme les caractéristiques personnelles et l’usage d’autres drogues. La relation ne
semblait pas résulter de l’usage du cannabis aux fins d’automédicamenter les symptômes de
psychose. Une relation causale concourante est biologiquement plausible parce que les troubles
psychotiques impliquent des perturbations des systèmes neurotransmetteurs de la dopamine, avec
lesquels le système cannabinoïde interagit, comme le démontrent des études animales et une étude
de provocation humaine.
Conclusion : Il est très plausible que l’usage du cannabis précipite la schizophrénie chez les
personnes qui sont vulnérables, en raison d’antécédents personnels ou familiaux de schizophrénie.
